Accessibility Menu
Enlivex Therapeutics logo

Enlivex Therapeutics

(NASDAQ) ENLV

Current Price$1.09
Market Cap$256.37M
Since IPO (2019)-90%
5 Year-92%
1 Year-4%
1 Month-2%

Enlivex Therapeutics Financials at a Glance

Market Cap

$256.37M

Revenue (TTM)

$0.00

Net Income (TTM)

$12.70M

EPS (TTM)

$-0.53

P/E Ratio

-2.02

Dividend

$0.00

Beta (Volatility)

0.80 (Low)

Price

$1.09

Volume

0

Open

$1.07

Previous Close

$1.09

Daily Range

$1.07 - $1.09

52-Week Range

$0.66 - $2.10

ENLV News

No articles available.

ENLV: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enlivex Therapeutics

Industry

Biotechnology

Employees

36

CEO

Oren Hershkovitz, PhD

Headquarters

Ness Ziona, 7403618, IL

ENLV Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-58%

Return on Capital

-83%

Return on Assets

-61%

Earnings Yield

-49.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$256.37M

Shares Outstanding

237.38M

Volume

0

Short Interest

0.00%

Avg. Volume

353.96K

Financials (TTM)

Gross Profit

$545.00K

Operating Income

$15.54M

EBITDA

$14.47M

Operating Cash Flow

$13.01M

Capital Expenditure

$103.00K

Free Cash Flow

$13.11M

Cash & ST Invst.

$23.61M

Total Debt

$534.00K

Enlivex Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$81.00K

+49.7%

Gross Margin

0.00%

N/A

Market Cap

$256.37M

N/A

Market Cap/Employee

$3.61M

N/A

Employees

71

N/A

Net Income

$2.21M

+15.3%

EBITDA

$2.12M

+28.2%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$17.61M

-25.8%

Accounts Receivable

$567.00K

-55.9%

Inventory

$0.00

-100.0%

Long Term Debt

$426.00K

+1.7%

Short Term Debt

$275.00K

-20.5%

Return on Assets

-60.66%

N/A

Return on Invested Capital

-82.65%

N/A

Free Cash Flow

$2.32M

+11.7%

Operating Cash Flow

$2.30M

+12.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRXSNeurAxis, Inc.
$7.16+2.43%
LSTALisata Therapeutics, Inc.
$5.02+0.20%
XCURExicure, Inc.
$4.75+7.22%
PASGPassage Bio, Inc.
$7.38+4.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$75.91+0.01%
IBITiShares Bitcoin Trust
$39.82-0.01%

Questions About ENLV

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.